Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MERTK | Q12866 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.40 |
| ▸ | GSR | P00390 | 2/20 | 0.40 |
| ▸ | TXNRD1 | Q16881 | 2/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56616 | 0.83 | MAPT (0.50) | MAPTALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL29364858 | 0.83 | MAPT (0.50) | MAPTALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL30875970 | 0.80 | NOS3 (0.48) | MAPTALDH1A1TDP1TSHRMEN1 | |
| SCHEMBL539616 | 0.80 | NOS3 (0.48) | MAPTALDH1A1TDP1TSHRMEN1 | |
| SCHEMBL671296 | 0.79 | TDP1 (0.45) | MAPTALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL29391396 | 0.79 | TDP1 (0.45) | MAPTALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL136263 | 0.78 | CTSB (0.53) | MAPTALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL30574931 | 0.78 | CTSB (0.53) | MAPTALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL2034272 | 0.76 | TDP1 (0.42) | MAPTALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL14665468 | 0.76 | TDP1 (0.44) | MAPTALDH1A1TDP1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570671-B2 | Substituted oxoisoindoline compounds for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4126843-B1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024253416-A1 | PYRIMIDINE/PYRIDINE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2024-12-12 | — | — | WO | disclosed |
| CN-115605466-B | Substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4126843-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115605466-A | Substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司（US） | 2023-01-13 | — | — | CN | disclosed |
| US-20220119348-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | OBLIQUE THERAPEUTICS AB (SE) | 2022-04-21 | — | — | US | disclosed |
| US-20220119348-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | OBLIQUE THERAPEUTICS AB (SE) | 2022-04-21 | — | — | US | disclosed |
| US-11161815-B2 | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | OBLIQUE THERAPEUTICS AB (SE) | 2021-11-02 | — | — | US | disclosed |
| CN-110382486-A | Heteroaryl sulfonyl substituted pyridines and their use in the treatment of cancer | 欧比力克治疗公司 | 2019-10-25 | — | — | CN | disclosed |
| WO-2018146472-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | OBLIQUE THERAPEUTICS AB (SE) | 2018-08-16 | — | — | WO | disclosed |
| WO-2018146469-A1 | HETEROARYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | OBLIQUE THERAPEUTICS AB (SE) | 2018-08-16 | — | — | WO | disclosed |
| EP-3331858-A1 | PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | Arnér, Elias, Set Jenö (SE) | 2018-06-13 | — | — | EP | disclosed |
| CN-108026044-A | Pyridines and their use in cancer therapy | E·S·J·阿内尔 | 2018-05-11 | — | — | CN | disclosed |
| WO-2017027359-A1 | PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017027359-A1 | PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-02-16 | — | — | WO | disclosed |
| WO-2013080215-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF FLUPIRTINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ARCH PHARMALABS LIMITED (IN) | 2013-06-06 | — | — | WO | disclosed |
| US-8053212-B1 | Non-standard nucleoside analogs with reduced epimerization | BENNER STEVEN ALBERT | 2011-11-08 | — | — | US | disclosed |
| US-4382937-A | Naphthyridine derivatives and their use as anti-bacterials | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1983-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119348-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | HCCS, ABL1, IDH1 | MAPT 4656/4885ALDH1A1 168/4885TDP1 1431/4885 |
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | DDX21, HRAS, RPL17 | MAPT 3829/4885ALDH1A1 1946/4885TDP1 1801/4885 |
| US-12570671-B2 | Substituted oxoisoindoline compounds for the treatment of cancer | NR3C1, NR2C2, RIOX2 | MAPT 4488/4885ALDH1A1 3404/4885TDP1 1517/4885 |
| US-11161815-B2 | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | HCCS, ABL1, IDH1 | MAPT 4656/4885ALDH1A1 168/4885TDP1 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.